tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Burkitt Lymphoma D002051 15 associated lipids
Burns D002056 34 associated lipids
Candidiasis, Oral D002180 11 associated lipids
Candidiasis, Vulvovaginal D002181 8 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Cardiomyopathy, Hypertrophic D002312 6 associated lipids
Cardiomyopathy, Restrictive D002313 1 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Catalepsy D002375 30 associated lipids
Cataract D002386 34 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Myoclonic Cerebellar Dyssynergia D002527 1 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Uterine Cervical Dysplasia D002578 2 associated lipids
Cheilitis D002613 2 associated lipids
Cholelithiasis D002769 16 associated lipids
Cholestasis D002779 23 associated lipids
Choline Deficiency D002796 16 associated lipids
Hemophilia B D002836 3 associated lipids
Chronic Disease D002908 7 associated lipids
Cicatrix D002921 9 associated lipids
Coccidioidomycosis D003047 2 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Collagen Diseases D003095 2 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Confusion D003221 4 associated lipids
Connective Tissue Diseases D003240 2 associated lipids
Corneal Diseases D003316 13 associated lipids
Cough D003371 19 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Crohn Disease D003424 12 associated lipids
Cryptococcosis D003453 3 associated lipids
Cutis Laxa D003483 1 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cystitis D003556 23 associated lipids
Phyllodes Tumor D003557 1 associated lipids
Hearing Loss, Sudden D003639 1 associated lipids
Deglutition Disorders D003680 2 associated lipids
Dehydration D003681 11 associated lipids
Demyelinating Diseases D003711 15 associated lipids
Dental Enamel Hypoplasia D003744 2 associated lipids
Dental Pulp Calcification D003784 2 associated lipids
Dermatitis D003872 30 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatitis, Atopic D003876 19 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Chen CH et al. Comparison of tuberculosis infection rates in a national database of renal transplant patients with data from a single center in Taiwan. 2014 Transplant. Proc. pmid:24656019
Tzakis AG et al. Two-year experience with FK 506 in pediatric patients. 1993 Transplant. Proc. pmid:7679822
Ochiai T et al. Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. 1991 Transplant. Proc. pmid:1721255
Pham SM et al. Tacrolimus (FK 506) in clinical cardiac transplantation: a five-year experience. 1996 Transplant. Proc. pmid:8623208
Demetris AJ et al. Pathologic observations in human allograft recipients treated with FK 506. 1990 Transplant. Proc. pmid:1689891
Undre NA et al. Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. 1998 Transplant. Proc. pmid:9636527
Nazmul MN et al. Severe Hyperkalemia Complicating Voriconazole Treatment in a Kidney Transplant Recipient With Histoplasmosis: A Case Report. 2017 Transplant. Proc. pmid:29198681
Sánchez-Fructuoso AI et al. The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. 2009 Jul-Aug Transplant. Proc. pmid:19715905
Büsing M et al. Mycophenolate mofetil/tacrolimus/single-shot versus azathioprine/cyclosporine/ATG in pancreas-kidney transplantation: results of a prospective randomized single-center study. 1998 Transplant. Proc. pmid:9532155
Gruessner RW et al. Mycophenolate mofetil and tacrolimus for induction and maintenance therapy after pancreas transplantation. 1998 Transplant. Proc. pmid:9532156
Bechstein WO et al. A comparative, randomized trial of concentration-controlled sirolimus combined with reduced-dose tacrolimus or standard-dose tacrolimus in renal allograft recipients. 2013 Jul-Aug Transplant. Proc. pmid:23953523
Zhao YJ et al. Late, severe, noninfectious diarrhea after renal transplantation: high-risk factors, therapy, and prognosis. 2013 Jul-Aug Transplant. Proc. pmid:23953533
Pedroso JA et al. Elderly kidney transplant recipient with intermittent fever: a case report of leishmaniasis with acute kidney injury during liposomal amphotericin B therapy. 2014 Transplant. Proc. pmid:25242789
Ichikawa Y et al. Acute rejection and the therapeutic choice of drug. 2000 Transplant. Proc. pmid:11119923
Morales JM et al. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients. 2005 Transplant. Proc. pmid:16386523
Lopes CT et al. Skin allograft survival and analysis of renal parameters after FTY720 + tacrolimus treatment in mice. 2008 Transplant. Proc. pmid:18455036
Charpentier B An induction versus no-induction protocol in anticalcineurin-based immunosuppression using very low-dose steroids. 2001 Transplant. Proc. pmid:11406262
Woan MC et al. Characterization of the biopsy growth assay in monitoring cardiac transplant patients for rejection. 1993 Transplant. Proc. pmid:7680171
Rilo HR et al. Effect of intraportal human islet transplantation on kidney graft survival in simultaneous kidney-islet allografts. 1993 Transplant. Proc. pmid:7680172
Francavilla A et al. The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. 1991 Transplant. Proc. pmid:1721287
Carobbi A et al. Synergism of splenectomy and immunosuppressive drugs in prolongation of cardiac xenograft survival. 1992 Transplant. Proc. pmid:1373543
Blanc P et al. Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. 1991 Transplant. Proc. pmid:1721288
Ueno M et al. Immunosuppressive effect in combination therapy of cyclosporine A, FK 506, and 15-deoxyspergualin on pancreatic islet xenotransplantation. 1992 Transplant. Proc. pmid:1373546
Kyo M et al. Results with histological diagnosis in kidney transplant rejections treated with 15-deoxyspergualin. 1996 Transplant. Proc. pmid:8623457
D'Silva M et al. Immunosuppressive effect of RS-61443 on rat cardiac allograft survival in combination with leflunomide or FK 506. 1996 Transplant. Proc. pmid:8623467
Ghobrial RM et al. Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. 1998 Transplant. Proc. pmid:9636597
Barreto P et al. Conversion From Twice-Daily to Once-Daily Tacrolimus in Stable Kidney Graft Recipients. 2016 Transplant. Proc. pmid:27742278
Murata M et al. Unrelated donor bone marrow transplantation in Japanese patients is facilitated by the National Marrow Donor Program of the United States. 1998 Transplant. Proc. pmid:9474987
Resch B et al. FK 506 and successful pregnancy in a patient after renal transplantation. 1998 Transplant. Proc. pmid:9474990
Basu A et al. Reversal of acute cellular rejection after renal transplantation with Campath-1H. 2005 Transplant. Proc. pmid:15848576
Moffatt SD et al. Comparative efficacy of liposomal FK 506 with FK 506 (tacrolimus) with and without anti-CD4/CD8 monoclonal antibodies. 1999 Transplant. Proc. pmid:10578277
Töz H et al. Comparison of tacrolimus and cyclosporin in renal transplantation by the protocol biopsies. 2004 Jan-Feb Transplant. Proc. pmid:15013324
Bachetoni A et al. Preliminary evaluation of the new TACR flex method versus MEIA method in the therapeutic monitoring of tacrolimus in organ transplantation. 2007 Jul-Aug Transplant. Proc. pmid:17692678
Pereira M et al. Hyperacute Rejection in a Kidney Transplant With Negative Crossmatch: A Case Report. 2016 Transplant. Proc. pmid:27742303
Woodle ES et al. FK 506 rescue therapy: early conversion improves efficacy. 1993 Transplant. Proc. pmid:7682359
Loss M et al. Influence of long-term cyclosporine or FK 506 therapy on glucose and lipid metabolism in stable liver graft recipients. 1995 Transplant. Proc. pmid:7533365
Woo J et al. Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. 1991 Transplant. Proc. pmid:1721319
Jin KB et al. Effects of tacrolimus on antioxidant status and oxidative stress in glioma cells. 2008 Transplant. Proc. pmid:18929850
Yoshimura N et al. Safety analysis after tacrolimus immunosuppression in renal transplant recipients in Japan: 5-year results in >1500 patients. 2005 Transplant. Proc. pmid:15919458
Sugitani A et al. Long-term results of tacrolimus therapy for renal transplantation in patients with diabetic nephropathy in Japan. 2005 Transplant. Proc. pmid:15919459
Tzakis AG et al. Campath-1H in intestinal and multivisceral transplantation: preliminary data. 2002 Transplant. Proc. pmid:12034248
Allers C et al. Tacrolimus, daclizumab, sirolimus, and budesonide after small bowel transplantation in order to reduce nephrotoxicity. 2002 Transplant. Proc. pmid:12034251
Böttiger Y et al. Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. 2002 Transplant. Proc. pmid:12176476
Hodge EE et al. Use of mycophenolate mofetil in liver transplant recipients experiencing renal dysfunction on cyclosporine or tacrolimus-randomized, prospective, multicenter study results. 2002 Transplant. Proc. pmid:12176477
Shirakata Y et al. The minimum graft size for successful orthotopic partial liver transplantation in the canine model. 1995 Transplant. Proc. pmid:7533422
Yuan-Xin L et al. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China. 2010 Jan-Feb Transplant. Proc. pmid:20172275
Alessiani M et al. CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721351
Schorlemmer HU and Kurrle R Combination therapy of malononitrilamides and tacrolimus (FK 506) induced long-term xenograft survival. 1998 Transplant. Proc. pmid:9865337
Ahlmén J et al. Positive effects of tacrolimus in a case of CIDP. 1998 Transplant. Proc. pmid:9865344
Sánchez-Pérez B et al. Influence of immunosuppression and effect of hepatitis C virus on new onset of diabetes mellitus in liver transplant recipients. 2008 Transplant. Proc. pmid:19010171
Gaber LW et al. Renal histology with varying FK506 blood levels. 1997 Feb-Mar Transplant. Proc. pmid:9122955
Alessiani M et al. Combined FK 506 and mycophenolate mofetil immunosuppression prolongs survival after small bowel transplantation in pigs. 1996 Transplant. Proc. pmid:8907922
Chamienia A et al. One-year observation of kidney allograft recipients converted from cyclosporine microemulsion to tacrolimus. 2006 Jan-Feb Transplant. Proc. pmid:16504670
Cohen DS et al. Porcine small bowel transplantation with rapamycin-based induction immunosuppression and short-course cyclosporine or FK 506 therapy. 1996 Transplant. Proc. pmid:8907923
Yoshimura R et al. Study of the effect of immunosuppressive agents on renal cytochrome P-450 system in the rat. 1994 Transplant. Proc. pmid:7520610
Kitamura M et al. Clinical experience of FK 506 for renal allograft transplantation. 1994 Transplant. Proc. pmid:7520611
Herrero JI et al. Conversion from calcineurin inhibitors to mycophenolate mofetil in liver transplant recipients with diabetes mellitus. 2003 Transplant. Proc. pmid:12962832
Youseff N and Small S A retrospective analysis of a sirolimus/prograf regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts. 2002 Transplant. Proc. pmid:12176522
Moutabarrik A et al. In vitro FK 506 kidney tubular cell toxicity. 1991 Transplant. Proc. pmid:1721383
McCauley J et al. Changes in renal function after liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721385
Sanada O et al. Establishment of chimerism in donors by intraportal injection of recipient-type bone marrow cells with concomitant administration of FK 506 before liver transplantation prolongs liver allograft survival in rats. 1998 Transplant. Proc. pmid:9838689
Kandaswamy R et al. Vascular graft thrombosis after pancreas transplantation: comparison of the FK 506 and cyclosporine eras. 1999 Feb-Mar Transplant. Proc. pmid:10083254
Youbin Z et al. Tumor Necrosis Factor-α-Induced Protein 8-Like 2 Gene Overexpression Prolongs the Survival of Rat Allogeneic Heart Allografts. 2015 Transplant. Proc. pmid:26518962
Tashiro H et al. Correlation of high-level microchimerism with graft acceptance in rat liver transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123287
Guckelberger O et al. Does the choice of primary immunosuppression influence the prevalence of cardiovascular risk factors after liver transplantation? 1996 Transplant. Proc. pmid:8962230
Aono T et al. Minimal threshold of FK 506 for enhancing liver regeneration in thymectomized rats. 1995 Transplant. Proc. pmid:7536981
Balbontin FG et al. Tacrolimus monitoring by simplified sparse sampling under the concentration time curve. 2003 Transplant. Proc. pmid:14611982
Bhaloo S and Prasad GV Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. 2003 Transplant. Proc. pmid:14611983
Saber LT et al. Posttransplantation conversion to sirolimus-based immunosuppression: a single center experience. 2007 Transplant. Proc. pmid:18089330
Migita K and Eguchi K FK 506-mediated T-cell apoptosis induction. 2001 Transplant. Proc. pmid:11377532
Omoto K et al. Adverse events in renal transplantation under tacrolimus/mycophnolate mofetil immunosuppression: a single-center experience. 2002 Transplant. Proc. pmid:12176591
Erickson LM et al. Gene expression profiles of rat heart allografts with immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11266960
Yamashita T et al. Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. 1991 Transplant. Proc. pmid:1721414
Sugito K et al. A comparative study of clinicopathologic characteristics of renal allografts under cyclosporine and FK506 immunosuppression. 1996 Transplant. Proc. pmid:8658683
Chung YW et al. Tacrolimus-Induced Apoptosis is Mediated by Endoplasmic Reticulum-derived Calcium-dependent Caspases-3,-12 in Jurkat Cells. 2018 Transplant. Proc. pmid:29731088
Dopazo C et al. Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin with rapamycin plus tacrolimus in liver transplant patient. 2009 Transplant. Proc. pmid:19376416
Peeters P et al. Economic evaluation of Neoral versus Sandimmune maintenance therapy for de novo liver transplant patients: results from an International Randomized Controlled Trial. Milton Study Group. 1998 Transplant. Proc. pmid:9723301
Eun SC et al. Prolongation of the rat composite tissue allograft survival by the combination of tolerogenic immature dendritic cells and short-term treatment with FK506. 2013 Transplant. Proc. pmid:23769045
Li Y et al. Long-term comparison of rat model of chronic allograft rejection of orthotopic small bowel transplantation induced by cyclosporine versus tacrolimus. 2013 Transplant. Proc. pmid:23769050
Liu W et al. Transfusion of endothelial cells with lentivirus-mediated expression of fas ligand prolonged survival of rat liver allograft. 2012 Transplant. Proc. pmid:22664023
Ishida S et al. Calcineurin Inhibitor-Induced Pain Syndrome in ABO-Incompatible Living Kidney Transplantation: A Case Report. Transplant. Proc. pmid:28104127
Kandaswamy R et al. Can we maintain immunosuppression avoiding nephrotoxic agents in pancreas transplantation? 2008 Transplant. Proc. pmid:18374118
Kanodia KV et al. Study of acute antibody-mediated rejection in renal allograft biopsies. 2008 Transplant. Proc. pmid:18555123
Jain A et al. Prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil: complete report on 350 primary adult liver transplantations. 2001 Feb-Mar Transplant. Proc. pmid:11267319
Propper DJ et al. Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. 1991 Transplant. Proc. pmid:1721446
Fabrega AJ et al. FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. 1991 Transplant. Proc. pmid:1721447
Viebahn R et al. Simulation of hypoxic and preservation injury in human hepatocyte cultures: influence of FK 506 and cyclosporine. 1993 Transplant. Proc. pmid:7689278
García Meseguer C et al. The effect of different immunosuppression on the outcome of pediatric renal transplants. 1999 Transplant. Proc. pmid:10500577
Torregrosa JV et al. Combined liver-kidney transplantation: our experience. 1999 Transplant. Proc. pmid:10500591
Morena M et al. Low-density lipoprotein composition and oxidation are not influenced by calcineurin inhibitors in renal transplant patients. 2000 Transplant. Proc. pmid:11134805
Fischer S et al. Initial experience of combined immunosuppressive induction therapy with polyclonal antithymocyte antibody, FK 506 (tacrolimus), and prednisolone in clinical liver transplantation. 2000 Transplant. Proc. pmid:11134815
Jensik SC Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. FK 506 Kidney Transplant Study Group. 1998 Transplant. Proc. pmid:9636494
Teng D et al. Comparison of rapamycin versus FK506 on expression of cytoprotective genes in the rat kidney allografts undergoing chronic allograft nephropathy. 2006 Transplant. Proc. pmid:16980034
Matsumoto S et al. ET-Kyoto ductal injection and density-adjusted purification combined with potent anti-inflammatory strategy facilitated single-donor islet transplantation: case reports. 2010 Jul-Aug Transplant. Proc. pmid:20692433
Bresci S et al. Case report: cystic fibrosis, lung transplantation, and the novel H1N1 flu. 2010 Jul-Aug Transplant. Proc. pmid:20692461
Braun F et al. Living-related versus living-unrelated kidney transplantation using tacrolimus initial immunosuppression. 2000 Transplant. Proc. pmid:10700989
Finni PE et al. Is hepatitis C a risk factor to posttransplant diabetes mellitus after renal transplantation in patients using tacrolimus? 2004 Transplant. Proc. pmid:15194303
White SA et al. Influence of delayed graft function in renal transplants from cadaveric or non-heart-beating donors. 2000 Transplant. Proc. pmid:10701018
Sens YA et al. Posttransplant diabetes mellitus in renal transplant patients with hepatitis C virus. 2004 Transplant. Proc. pmid:15194304
Nakamura A et al. Effects of elevated tacrolimus trough levels in association with infectious enteritis on graft function in renal transplant recipients. 2014 Transplant. Proc. pmid:24656020